Filtered By:
Infectious Disease: Hepatitis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Rare case report: a 26-year-old man with Eales' disease
Conclusion: Despite the aggressive treatment with oral steroids, immunosuppressants, and anti-VEGF injections, there were many exacerbations, and remission was not achieved. As a result, aggressive neovascular glaucoma developed, which led to total blindness in the left eye and legal blindness in the right eye. Abbreviations: HLA = human leukocyte antigens, Anti-VEGF = vascular endothelial growth factor inhibitors, BCVA = best corrected visual acuity, FA = fundus angiography, HBsAg = hepatitis B surface antigen, Anti-HCV = hepatitis C antibodies, TPHA = Treponema Pallidum hemagglutination assay, PCR = polymerase chain reac...
Source: Herpes - July 31, 2023 Category: Infectious Diseases Authors: Sandra Bleidele Igors Solomatins A īda Macijevska Source Type: research

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Effect of Long-term Oral Steroids on Intraocular Pressure in Children With Autoimmune Hepatitis: a Prospective Cohort Study
Objective: Topical corticosteroids are known to cause raised intraocular pressure (IOP). However, there is a scarcity of literature regarding systemic steroids-induced raised IOP in children. The authors aimed to evaluate the IOP in children with autoimmune hepatitis (AIH) receiving oral prednisone. Methods: In this prospective study, children (1 to 18 y) with newly diagnosed AIH who received oral prednisone (July 2016 to December 2017) were included. Comprehensive ophthalmic check-up, including visual acuity, IOP, slit-lamp, and fundus examinations were done before and at 1, 3, and 6 months of follow-up. IOP ≥20...
Source: Journal of Glaucoma - October 1, 2019 Category: Opthalmology Tags: Original Studies Source Type: research

The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study.
CONCLUSIONS: This study showed no differences in biochemical response between the groups. Lower, although not significantly, rate of adverse effects and lower total number of adverse effects indicate that BUD/AZA may potentially be used as the first-line treatment of choice, especially in patients with obesity, diabetes, resistant hypertension, glaucoma, or osteoporosis. PMID: 31483120 [PubMed - in process]
Source: Croatian Medical Journal - August 30, 2019 Category: General Medicine Authors: Binicier OB, Günay S Tags: Croat Med J Source Type: research

UCLA volunteers provide free health care at downtown L.A. mega clinic
With the strongly held belief that access to health care should be available to everyone — not just the insured — nearly 200 volunteers from UCLA joined an effort to provide free services to more than 2,000 people at a three-day Care Harbor community clinic.“Los Angeles is still one of the leading areas of people without insurance or access to care and it’s a problem for the community,” said Dr. Patrick Dowling, professor and chair of the  UCLA Department of Family Medicine, who led the UCLA volunteer contingent at Care Harbor ’s seventh health care mega clinic. “I’m involved with this because I know ther...
Source: UCLA Newsroom: Health Sciences - January 4, 2018 Category: Universities & Medical Training Source Type: news

Arkansas to Accept Medical Marijuana Card Applications
LITTLE ROCK — Arkansas' medical marijuana industry will ramp up in the next week, with the state poised to accept applications from potential patients, growers and distributors. Beginning Friday, the state Medical Marijuana Commission will accept applications from those hoping to grow or supply marijuana, while the Health Department will take applications from those hoping to benefit from the first marijuana-as-medicine program in the Bible Belt. The application periods will run until Sept. 18. State officials expect anywhere from 20,000 to 40,000 people to seek permission to use the drug for a number of health probl...
Source: Arkansas Business - Health Care - June 26, 2017 Category: American Health Source Type: news

High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Abstract As syndromic short stature and overgrowth are heterogeneous and the list of causative genes is rapidly expanding, there is an unmet need for identifying genetic causes based on conventional gene testing or karyotyping. Early diagnosis leads to the proper management of the patient and providing genetic counseling for family members at risk in a timely manner. We conducted targeted exome sequencing to identify the genetic causes of undiagnosed syndromic short stature or overgrowth in 15 pediatric patients from 13 families in Korea. We applied targeted exome sequencing using the Next Seq platform and a TruSi...
Source: Clinical Genetics - April 20, 2017 Category: Genetics & Stem Cells Authors: Kim YM, Lee YJ, Park JH, Lee HD, Cheon CK, Kim SY, Hwang JY, Jang JH, Yoo HW Tags: Clin Genet Source Type: research

In the Workplace 2017: How Arkansas Employers Can Deal with Medical Marijuana
Editor's Note: This is the first of five articles this week by the labor and employment team at the law firm of Wright Lindsey Jennings of Little Rock examining key trends for employers and the workplace in 2017. Here's a quick look at important employment issues that could arise next year. Now that Arkansas is the latest state to have a medical marijuana law on the books, Arkansas employers must be prepared to address this issue. Although the amendment to the Arkansas Constitution is effective immediately, it should take some time for most Arkansas residents to take advantage of the approved use of medical ...
Source: Arkansas Business - Health Care - December 26, 2016 Category: American Health Source Type: news

Arkansas Medical Marijuana Commission Members to be Named
LITTLE ROCK - Members of the Arkansas Medical Marijuana Commission are to be announced. Gov. Asa Hutchinson, Senate President Pro Tem Jonathan Dismang and House Speaker Jeremy Gillam are to announce the appointments Wednesday at the state Capital. The five-member commission is to administer and regulate the licensing of medical marijuana dispensaries and cultivation facilities in the state. It is to begin accepting applications for the dispensaries by June. Voters in November passed a state constitutional amendment legalizing medical marijuana for patients with certain conditions, including cancer, glaucoma, Tour...
Source: Arkansas Business - Health Care - December 7, 2016 Category: American Health Source Type: news

Medical Marijuana: A Fact of Life for Arkansas Employers (Stuart Jackson Commentary)
The election is over, and Arkansas is now the latest of many states to have a medical marijuana law on the books.  Although the new amendment to the Arkansas Constitution is effective immediately, it should take some time for the approved use of medical marijuana to begin. At the very least, someone has to design and print the required "Registry Identification Cards" for users — unless one of your employees shows up with a registry identification card from another state and claims to be a "visiting qualifying patient."   So, what does the new law do? It allows (among other things) "qualifying patients" who ...
Source: Arkansas Business - Health Care - November 10, 2016 Category: American Health Source Type: news

Development of C-Methyl Branched Purine Ribonucleoside Analogs: Chemistry, Biological Activity and Therapeutic Potential.
Abstract In this review, we first highlighted on C-methyl-branched nucleosides and nucleotides approved as anti-hepatitis C infection (HCV) drugs, their mechanism of action and recent progress in the development of new clinical candidates. Then, we report on our attempt to develop several C-methyl nucleosides/tides potentially useful for treatment of various diseases such cancer, pain, epilepsy and glaucoma. Design, synthesis and pharmacological screening of 1'-C-, 2'-C-, 3'-C-methyladenosine or other purine/pyrimidine nucleosides allowed us to discover some promising new molecules. 3'-C-Methyladenosine showed ant...
Source: Current Medicinal Chemistry - June 25, 2016 Category: Chemistry Authors: Petrelli R, Grifantin M, Cappellacci L Tags: Curr Med Chem Source Type: research

Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders.
Abstract The present investigation aimed to provide an objective narrative review of the existing literature pertaining to the benefits and harms of marijuana use for the treatment of the most common medical and psychological conditions for which it has been allowed at the state level. Common medical conditions for which marijuana is allowed (i.e., those conditions shared by at least 80 percent of medical marijuana states) were identified as: Alzheimer's disease, amyotrophic lateral sclerosis, cachexia/wasting syndrome, cancer, Crohn's disease, epilepsy and seizures, glaucoma, hepatitis C virus, human immunodefici...
Source: Addiction Science and Clinical Practice - April 24, 2015 Category: Addiction Authors: Belendiuk KA, Baldini LL, Bonn-Miller MO Tags: Addict Sci Clin Pract Source Type: research

Vitamins: stop taking the pills
This article was corrected on 7 June 2013. During editing, a line in the fifth from last paragraph, beginning 'Another example is St John's wort…' was accidentally transposed, leading to the suggestion that serotonin was a medicine rather than a brain chemical.Alternative medicineHealth & wellbeingHealthCancerCancerMedical researchPharmaceuticals industryDepressionguardian.co.uk © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds    
Source: Guardian Unlimited Science - June 7, 2013 Category: Science Tags: The Guardian Depression Pharmaceuticals industry Health Medical research & wellbeing Society Extracts Features Cancer Life and style Alternative medicine Science Source Type: news